
Julie E Ledgerwood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3376060/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
2	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet, The, 2018, 391, 552-562.	13.7	235
3	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet, The, 2014, 384, 2046-2052.	13.7	206
4	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infectious Diseases, The, 2011, 11, 916-924.	9.1	174
5	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Medicine, 2018, 15, e1002493.	8.4	174
6	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. Journal of Infectious Diseases, 2011, 203, 1396-1404.	4.0	138
7	Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect. Journal of Infectious Diseases, 2013, 208, 418-422.	4.0	117
8	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet, The, 2015, 385, 1545-1554.	13.7	109
9	Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial. Journal of Infectious Diseases, 2015, 211, 549-557.	4.0	108
10	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet, The, 2019, 393, 889-898.	13.7	99
11	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV,the, 2019, 6, e667-e679.	4.7	67
12	Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. Human Vaccines and Immunotherapeutics, 2014, 10, 3446-3454.	3.3	50
13	DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin, 2009, 5, 623-626.	2.4	27
14	An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. Npj Vaccines, 2017, 2, 15.	6.0	24
15	DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial. PLoS ONE, 2018, 13, e0206837.	2.5	24
16	Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults. PLoS ONE, 2015, 10, e0123969.	2.5	22
17	Filovirus emergence and vaccine development: AÂperspective for health care practitioners in travel medicine. Travel Medicine and Infectious Disease, 2011, 9, 126-134.	3.0	18
18	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE, 2019, 14, e0222178.	2.5	18

#	Article	IF	CITATIONS
19	DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial. PLoS ONE, 2015, 10, e0125914.	2.5	17
20	Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. Contemporary Clinical Trials, 2015, 44, 112-118.	1.8	12
21	Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort. Lancet Infectious Diseases, The, 2015, 15, 1117-1119.	9.1	9
22	AS03-adjuvanted influenza vaccine in elderly people. Lancet Infectious Diseases, The, 2013, 13, 466-467.	9.1	6